Updated on 2 May 2012
CytoPharm (CP) is developing oral interferon for the treatment of hepatitis C under phase II clinical trials. CP also initiates clinical study for flu this year. On the other side, Cyto Biotech, which is developing oral interferon for animal healthcare, is expanding its market into mainland China this year. The company plans to list on Taiwan OTC market later this year.
ACTS Biosciences has launched global marketing of its comprehensive and high quality genomics/pharmacogenomics services and diagnostic products and services to various clients including pharmaceutical companies, CRO companies and diagnostic companies. ACTS has established its offices in Taiwan, China and the US to explore new business opportunities world-wide with specific emphasis in oncology-related diagnostics and therapies.
In addition to maintaining healthy growth, Vita Genomics is actively participating in modernizing Taiwan healthcare system. The company is establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future.
Year 2009 is a financially significant year for Vita Genomics, as it is the first year the company has achieved break-even point at over $5 million annual burn rate after nine years of its operations. The cumulated total number of peer-reviewed paper publication too has reached a new high of 53 with 13 patents.
On the R&D front, Vita Genomics has established several additional collaborations with major hospitals and premier academic institutes. Cancer targeted therapy is gaining momentum at local markets in Taiwan and through collaborations the company is increasing the detection services such as EGFR & Kras genes.
Establishment of ACTS Biosciences has increased its business horizons to other countries in the Asia Pacific region and worldwide. ACTS has established collaborations with top international pharmaceutical, CRO and diagnostic companies in 2009, which will generate additional revenues in future. Furthermore, with the establishment of another sister company, Cyto Biotech, the application of preventive care has also extended into animal uses.